Atul Sobti, boss of Ranbaxy, an Indian generics firm bought last year by Novartis, a Japanese pharmaceutical giant, offers a different reason for scepticism.

去年被日本制药公司Novartis买下的印度非专利药品公司Ranbaxy的经理Atul Sobti却对这种怀疑给出了不同的原因。

youdao

Atul Sobti, boss of Ranbaxy, an Indian generics firm bought last year by Daiichi Sankyo, a Japanese pharmaceutical giant, offers a different reason for scepticism.

ECONOMIST: Big drug firms embrace generics

Ranbaxy's board, which met Sunday in New Delhi, named Tsutomu Une, a senior Daiichi executive and a director on Ranbaxy's board, as chairman and elevated Atul Sobti, Ranbaxy's chief operating officer since 2007, to CEO and managing director.

FORBES: Business Billionaires